Bayer AG Q1 2026 core earnings per share €2.71 beat expectations, EBITDA €4.45bn up 9%, shares rose >6%.
Group sales €13.41bn slightly below forecasts, but currency‑adjusted sales rose 4.1%; net income €2.76bn exceeded €1.58bn estimate.
Crop Science division sales €7.56bn (+6.8% adj.), EBITDA €3.01bn (+17.9%); Pharmaceuticals sales €4.25bn (-0.5% adj.) with mixed product performance.
Free cash flow negative €2.32bn due to €2bn litigation payments; net financial debt rose to €32.52bn; FY2026 outlook unchanged.